| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Nebojsa Janjic | |
| Larry Gold | |||
| Daniel W Drolet | |||
| Louis S Green | |||
| P2860 | cites work | Crystal structure of human platelet-derived growth factor BB | Q24293538 |
| Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor | Q24294262 | ||
| Drusen complement components C3a and C5a promote choroidal neovascularization | Q24303123 | ||
| Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor | Q24320710 | ||
| The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor | Q24328901 | ||
| VEGF-Trap: a VEGF blocker with potent antitumor effects | Q24535043 | ||
| Structural and functional studies on platelet-derived growth factor | Q24555662 | ||
| cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor | Q24612837 | ||
| Ranibizumab and bevacizumab for neovascular age-related macular degeneration | Q24616209 | ||
| Complement in age-related macular degeneration: a focus on function | Q24635874 | ||
| Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes | Q24644120 | ||
| Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors | Q24676378 | ||
| Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors | Q24678647 | ||
| Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis | Q24684263 | ||
| Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets | Q27675037 | ||
| Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase | Q27860794 | ||
| In vitro selection of RNA molecules that bind specific ligands | Q27861109 | ||
| An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration | Q28190470 | ||
| Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria | Q28256613 | ||
| High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding | Q36696770 | ||
| Vitreous injections of pegaptanib sodium triggering allergic reactions | Q36743200 | ||
| Complement in immune and inflammatory disorders: therapeutic interventions | Q36756854 | ||
| Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. | Q36766439 | ||
| Inhibitory DNA ligands to platelet-derived growth factor B-chain | Q36832312 | ||
| Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor | Q36846788 | ||
| Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor | Q36893265 | ||
| Imino proton exchange rates imply an induced-fit binding mechanism for the VEGF165-targeting aptamer, Macugen. | Q36973203 | ||
| Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances | Q37065943 | ||
| Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors | Q37370535 | ||
| An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris | Q37413610 | ||
| Genetic control of the alternative pathway of complement in humans and age-related macular degeneration | Q37471769 | ||
| VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. | Q37582957 | ||
| Immunology of age-related macular degeneration | Q37614752 | ||
| Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line | Q37694752 | ||
| Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib | Q37916088 | ||
| RNA-based therapeutics: current progress and future prospects. | Q37979387 | ||
| Developing microRNA therapeutics | Q37981141 | ||
| Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature | Q38110731 | ||
| Immunogenicity of therapeutic proteins: influence of aggregation | Q38126938 | ||
| Current progress on aptamer-targeted oligonucleotide therapeutics | Q38168595 | ||
| Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy | Q38168825 | ||
| Discussion about several potential drawbacks of PEGylated therapeutic proteins | Q38170970 | ||
| Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5'-terminal with poly(ethylene glycol). | Q38298397 | ||
| Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys | Q38301978 | ||
| Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor | Q38305186 | ||
| Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model | Q38306798 | ||
| Characterization of an in vitro-selected RNA ligand to the HIV-1 Rev protein | Q38312216 | ||
| Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro | Q38318856 | ||
| Derivation of RNA aptamer inhibitors of human complement C5. | Q38322785 | ||
| 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain | Q38335060 | ||
| A SELEX primer | Q38363376 | ||
| Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. | Q39740070 | ||
| Transport of molecules in the tumor interstitium: a review | Q39768023 | ||
| An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody | Q40140583 | ||
| Synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates | Q40402078 | ||
| Nucleoside conformation is determined by the electronegativity of the sugar substituent. | Q40480998 | ||
| Modified RNA sequence pools for in vitro selection | Q40523091 | ||
| Platelet-derived growth factor receptor signals | Q40554673 | ||
| Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal | Q40848490 | ||
| Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation | Q40937602 | ||
| Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells | Q41144930 | ||
| Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells | Q41217559 | ||
| Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity | Q41292409 | ||
| Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. | Q41760990 | ||
| Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. | Q42021723 | ||
| Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies | Q42806048 | ||
| Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors | Q43578049 | ||
| Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration | Q43943551 | ||
| Quantification of 2'-fluoro-2'-deoxyuridine and 2'-fluoro-2'-deoxycytidine in DNA and RNA isolated from rats and woodchucks using LC/MS/MS. | Q44064700 | ||
| Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy | Q44164588 | ||
| The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency | Q44317160 | ||
| VEGF164Is Proinflammatory in the Diabetic Retina | Q44417311 | ||
| Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration | Q44443130 | ||
| Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival | Q44659145 | ||
| Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms | Q44680981 | ||
| A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. | Q45158856 | ||
| Pegaptanib for neovascular age-related macular degeneration | Q45206481 | ||
| VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death | Q45863485 | ||
| Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. | Q45877621 | ||
| Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study | Q46065497 | ||
| Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products | Q46082002 | ||
| Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family | Q46135963 | ||
| Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo | Q46159585 | ||
| Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). | Q46969340 | ||
| Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study). | Q47995257 | ||
| Systemic complement activation in age-related macular degeneration | Q28285925 | ||
| Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice | Q28504776 | ||
| Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 | Q28507115 | ||
| Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities | Q28508460 | ||
| Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor | Q28509882 | ||
| Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization | Q28513118 | ||
| Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer | Q28574927 | ||
| Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. | Q28583917 | ||
| Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium | Q28587604 | ||
| Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice | Q28593600 | ||
| High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis | Q28594191 | ||
| Vascular endothelial growth factor is a secreted angiogenic mitogen | Q28646475 | ||
| Aptamer-based multiplexed proteomic technology for biomarker discovery | Q28744329 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene | Q29547732 | ||
| Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele | Q29547733 | ||
| Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo | Q29614729 | ||
| Pericyte loss and microaneurysm formation in PDGF-B-deficient mice | Q29615196 | ||
| Ranibizumab for neovascular age-related macular degeneration | Q29617549 | ||
| Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid | Q29617640 | ||
| Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis | Q29617644 | ||
| Ocular drug delivery | Q30475605 | ||
| Human retinal molecular weight exclusion limit and estimate of species variation | Q30919500 | ||
| Liposome-anchored vascular endothelial growth factor aptamers | Q32022095 | ||
| The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. | Q33301664 | ||
| Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities | Q33491173 | ||
| Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. | Q33491174 | ||
| Discovery and development of therapeutic aptamers. | Q33522441 | ||
| Expanding the chemistry of DNA for in vitro selection | Q33536734 | ||
| Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation | Q33656940 | ||
| A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo | Q33688219 | ||
| Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy | Q33834772 | ||
| PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor | Q33945092 | ||
| New insight into clinical development of nucleic acid aptamers. | Q33945103 | ||
| Complement and its role in innate and adaptive immune responses | Q34088142 | ||
| The complement system | Q34137841 | ||
| A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165 | Q34245063 | ||
| Aptamers as therapeutics. | Q51813594 | ||
| A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. | Q52529779 | ||
| Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. | Q52553091 | ||
| Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. | Q52886344 | ||
| An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax). | Q54177011 | ||
| Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells | Q67590241 | ||
| Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes | Q67923126 | ||
| Vascular permeability factor, an endothelial cell mitogen related to PDGF | Q69116052 | ||
| Delivery of molecular medicine to solid tumors | Q70995735 | ||
| Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR | Q71058989 | ||
| Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes | Q71215521 | ||
| Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes | Q71585776 | ||
| PDGF and its receptors in the developing rodent retina and optic nerve | Q72563337 | ||
| Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys | Q73073460 | ||
| Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies | Q73077132 | ||
| Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway | Q73333644 | ||
| Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis | Q73794083 | ||
| Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions | Q77352961 | ||
| Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus | Q78811698 | ||
| VEGF/VPF: the angiogenesis factor found? | Q80505577 | ||
| Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 | Q80553646 | ||
| Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit | Q81362459 | ||
| Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration | Q86857727 | ||
| Complement-targeted therapeutics | Q34255011 | ||
| Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. | Q34292373 | ||
| Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 | ||
| Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells | Q34306017 | ||
| Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy | Q34324536 | ||
| Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study | Q34346463 | ||
| Platelet-derived growth factor D, tissue-specific expression in the eye, and a key role in control of lens epithelial cell proliferation | Q34378343 | ||
| Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease | Q34499843 | ||
| Complement activation and inflammatory processes in Drusen formation and age related macular degeneration | Q34521109 | ||
| A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. | Q34522196 | ||
| Vascular endothelial growth factor: basic science and clinical progress | Q34549887 | ||
| The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing | Q34582371 | ||
| Age-related macular degeneration: insights into inflammatory genes | Q34588628 | ||
| Ranibizumab versus verteporfin for neovascular age-related macular degeneration. | Q34652928 | ||
| Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 | Q34981750 | ||
| Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration | Q35064666 | ||
| Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization | Q35088365 | ||
| Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents | Q35309726 | ||
| Complement factor D in age-related macular degeneration | Q35593260 | ||
| VEGF: a critical player in neurodegeneration | Q35618967 | ||
| Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice | Q35633511 | ||
| Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution | Q35779820 | ||
| Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth | Q35788937 | ||
| Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment | Q35829410 | ||
| Modified deoxyoligonucleotides stable to exonuclease degradation in serum | Q35913882 | ||
| Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H Tyr⁴⁰²His polymorphism. | Q36218190 | ||
| Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family | Q36310102 | ||
| Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes | Q36367219 | ||
| Immunogenicity of biopharmaceuticals | Q36588728 | ||
| Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration | Q36619213 | ||
| Molecular mechanisms of VEGF-A action during tissue repair | Q36636355 | ||
| Challenges and obstacles of ocular pharmacokinetics and drug delivery | Q36650427 | ||
| Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor | Q36679836 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ophthalmology | Q161437 |
| eye disease | Q3041498 | ||
| nucleotide | Q28745 | ||
| nucleotide aptamers | Q49849144 | ||
| biomedical investigative technique | Q66648976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 127-46 | |
| P577 | publication date | 2016-06-01 | |
| P1433 | published in | Nucleic Acid Therapeutics | Q19297428 |
| P1476 | title | Fit for the Eye: Aptamers in Ocular Disorders | |
| P478 | volume | 26 |
| Q92528001 | A DNA-Based Biosensor Assay for the Kinetic Characterization of Ion-Dependent Aptamer Folding and Protein Binding |
| Q92903718 | Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease |
| Q52347485 | Aptamer Therapeutics in Cancer: Current and Future. |
| Q39070782 | Aptamers as Therapeutics |
| Q38290290 | Aptamers as targeted therapeutics: current potential and challenges |
| Q47150038 | Aptamers as the Agent in Decontamination Assays (Apta-Decontamination Assays): From the Environment to the Potential Application In Vivo |
| Q64058860 | Delivery of Cell-Specific Aptamers to the Arterial Wall with an Occlusion Perfusion Catheter |
| Q38609277 | Discovery of Aptamer Ligands for Hepatic Stellate Cells Using SELEX. |
| Q92486976 | Emerging roles of lncRNA in cancer and therapeutic opportunities |
| Q36266158 | Evolution of Complex Target SELEX to Identify Aptamers against Mammalian Cell-Surface Antigens |
| Q48087924 | Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics. |
| Q38851919 | From the RNA world to the clinic |
| Q36198637 | G-quadruplex-based aptamers against protein targets in therapy and diagnostics. |
| Q92492871 | Molecular affinity rulers: systematic evaluation of DNA aptamers for their applicabilities in ELISA |
| Q48227262 | Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease. |
| Q47109727 | Pharmacokinetic Properties of DNA Aptamers with Base Modifications |
| Q37570010 | Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer. |
| Q90439921 | Polymer-drug conjugate therapeutics: advances, insights and prospects |
| Q38291786 | Post-ExSELEX stabilization of an unnatural-base DNA aptamer targeting VEGF165 toward pharmaceutical applications |
| Q38287714 | RNA aptamers targeted for human αA-crystallin do not bind αB-crystallin, and spare the α-crystallin domain |
| Q64056800 | Selection of a novel DNA aptamer against OFA/iLRP for targeted delivery of doxorubicin to AML cells |
| Q64067864 | Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model |
| Q38436237 | The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study |
| Q38664824 | The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study |
| Q64076633 | Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules |
Search more.